371
Views
11
CrossRef citations to date
0
Altmetric
Reviews

Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice

&
Pages 363-375 | Received 15 May 2008, Accepted 28 Nov 2009, Published online: 28 Dec 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Tara Kroll, Mary B. Ames, Julie A. Pruett & Timothy S. Fenske. (2010) Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. Leukemia & Lymphoma 51:9, pages 1-3.
Read now

Articles from other publishers (9)

Anupama Rambhatla, Michael R. Strug, Jessica Garcia De Paredes, Marcos I. Cordoba Munoz & Mili Thakur. (2021) Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review. Journal of Assisted Reproduction and Genetics 38:8, pages 1897-1908.
Crossref
Mururul Aisyi, Ayu Hutami Syarif, Nur Asih & Agus Kosasih. (2020) Tyrosine kinase inhibitor resistance in pediatric chronic myeloid leukemia: a case report. Medical Journal of Indonesia 29:4, pages 427-30.
Crossref
Zijun Zhou, Yang Wang, Jun Li, Baichun Hu, Xiaolin Lin, Ye Chen, Rui Wang, Ju Liu & Hongsheng Liu. (2018) Design, synthesis, and biological evaluation of Cyclobentinib (CB1107) as a potential anti-CML agent. Medicinal Chemistry Research 27:8, pages 1863-1875.
Crossref
Miao Gao, Zheng-Lan Huang, Kun Tao, Qing Xiao, Xin Wang, Wei-Xi Cao, Min Xu, Jing Hu & Wen-Li Feng. (2016) Depression of oncogenecity by dephosphorylating and degrading BCR-ABL. Oncotarget 8:2, pages 3304-3314.
Crossref
Naif Alhawiti, Kate L. Burbury, Faith A. Kwa, Cindy J. O'Malley, Peter Shuttleworth, Mohamad Alzard, Abdullah Hamadi, Andrew P. Grigg & Denise E. Jackson. (2016) The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thrombosis Research 145, pages 54-64.
Crossref
Rafael RosellRafael Rosell. 2012. Molecular-Based Decision Making for Personalized Cancer Management. Molecular-Based Decision Making for Personalized Cancer Management 6 26 .
Victor Hugo Villar, Oliver V?gler, Jordi Mart?nez-Serra, Rafael Ramos, Silvia Calabuig-Fari?as, Antonio Guti?rrez, Francisca Barcel?Javier Mart?n-Broto & Regina Alemany. (2012) Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas. PLoS ONE 7:5, pages e37735.
Crossref
Li Liu, Renan Chen, Siyong Huang, Yanlan Wu, Guohui Li, Qiang Liu, Dandan Yin & Yingmin Liang. (2010) Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy. Medical Oncology 28:3, pages 835-839.
Crossref
Amina HaoualaNicolas WidmerMichel A. Duchosal, Michael Montemurro, Thierry BuclinLaurent A. Decosterd. (2011) Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117:8, pages e75-e87.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.